Moderna And Pfizer COVID-19 Vaccine Struggles Against South Africa Variant AS Johnson & Johnson Shot Goes Into Distribution

The fight against COVID-19 is far from over going by the rate at which the virus is mutating, giving rise to variants showing strong resistance vaccines already in circulation. A new study has once again cast doubts over Pfizer’s Inc. (NYSE: PFE) and Moderna Inc. (NASDAQ: MRNA)’s COVID-19 vaccine effectiveness in combating a deadly variant found in South Africa.

South Africa Covid Variant

According to the study, the percentage of antibodies created by Moderna’s vaccine to neutralize the South African variant B.1.351 was 12.4 times lower than the original coronavirus. Likewise, the Pfizer vaccine was 10.3 times lower in neutralizing the new variant than the original variant on which it was tested.

First detected in South African the variant B.1.351 has already found its way into 20 states in the US, with more than 80 cases already reported. The development raises serious concerns about whether the vaccines have what it takes to bring the pandemic under control once and for all.

Vaccines failing to generate the required antibodies to combat the virus will significantly jeopardize the push to keep infection rates low. Likewise, it raises serious questions about whether there will ever be a vaccine capable of combating any variant.

Johnson & Johnson Shot

While the Moderna and the Pfizer shots appear to be struggling against the South African variant, the Johnson & Johnson shot is now available in San Diego. The vaccine is being distributed the same way as the other two.

However, the Johnson & Johnson (NYSE: JNJ) vaccine is already facing some resistance, given that it was 72% effective in research trials in the US. Given that Moderna and Pfizer shots’ posted efficacy levels of more than 90% raise serious questions about the Johnson shot effectiveness.

Health officials have been forced into a PR drive reiterating that the Johnson & Johnson shot is as effective as the rest approved for emergency use. However, it is still unclear as to whether it is well suited at handling the South African coronavirus variant.

By reading our website you agree to the terms of our disclaimer, which are subject to change at any time. Owners and affiliates are not registered or licensed in any jurisdiction whatsoever to provide financial advice or anything of an advisory nature. Always do your own research and/or consult with an investment professional before investing. Low priced stocks are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold us, our editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters, website, twitter, Facebook or chat. We do not advise any reader to take any specific action. Our releases are for informational and educational purposes only. Never invest purely based on our articles. Gains mentioned on our website, twitter, Facebook, and on our website may be based on EOD or intraday data. We may be compensated for the production, release, and awareness of this article. We will disclose any and all compensation on the article page. This publication and its owner never hold positions in the securities mentioned in our articles. Our information may contain Forward-Looking Statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site. The information in our disclaimers is subject to change at any time without notice. We are not held liable or responsible for the information in press releases issued by the companies discussed in these write-ups. Please do your own due diligence